key: cord-0767887-q4yfoda3 authors: Kodana, Masahiro; Kitagawa, Yutaro; Takahashi, Rina; Matsuoka, Masaru; Fushimi, Naoki; Sakai, Jun; Ishibashi, Noriomi; Imai, Kazuo; Takeuchi, Shinichi; Tarumoto, Norihito; Maesaki, Shigefumi; Ikezono, Tetsuo; Maeda, Takuya title: Concerns about the clinical usefulness of saliva specimens 1 for the diagnosis of COVID-19 date: 2021-04-16 journal: J Infect DOI: 10.1016/j.jinf.2021.04.007 sha: e12a6ce88b6b4f11cf3199330e12b86d76b9d632 doc_id: 767887 cord_uid: q4yfoda3 nan material for the diagnosis of coronavirus disease 2019 (COVID-19) [1] . A large number of studies have demonstrated that saliva samples are more sensitive than nasopharyngeal (NP) swab specimens for the detection of SARS-CoV-2, and it has also been well documented that saliva is a suitable alternative to an NP swab. However, studies comparing saliva samples to NP swabs have reported conflicting results [2] . In some studies demonstrating the usefulness of saliva specimens, the study population was limited to asymptomatic or mild COVID-19 cases [3, 4] . To understand the performance of saliva samples in more detail, we evaluated the diagnostic concordance of saliva specimens derived from COVID-19 patients with molecular diagnostic tools and an automated SARS-CoV-2 antigen test, both widely used in diagnostic laboratories. Thirty-five Japanese patients, who were admitted to Saitama Medical University Hospital in Japan from June 5 to July 31, 2020, were enrolled in this prospective study after being diagnosed with COVID-19. Their definitive diagnosis was confirmed with reverse transcription quantitative PCR (RT-qPCR) using NP swab specimens in accordance with the nationally recommended protocol [5] . After hospitalization, all participants were instructed to collect saliva samples repeatedly in a sterile sputum container before lunch after not eating or drinking for 30 min until approximately 2 mL of saliva was obtained. They were required to produce one sample every 3 days for up to 2 weeks. All participants were informed that they could withdraw participation at any time and sampling ended at discharge. The saliva specimens were subjected to the following three procedures: (1) RNA extraction for a nucleic acid amplification test for SARS-CoV-2; (2) direct reverse transcription loop-mediated isothermal amplification (RT-LAMP) without RNA extraction; and (3) a LUMIPULSE ® SARS-CoV-2 Ag test kit (Fujirebio, Tokyo, Japan) with the chemiluminescence enzyme immunoassay method, as described previously [6] . For RNA extraction, the samples were diluted 1:1 with 1× phosphate-buffered saline (PBS) and homogenized by vortexing for 15 s. Subsequently, RNA extraction was performed with a QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany) following the manufacturer's instructions. RNA was finally eluted in 60 μL of the provided AVE buffer. RNA was used as a template for the RT-qPCR and RT-LAMP methods. Conventional RT-qPCR for the specific amplification of the N2 gene of SARS-CoV-2 was performed using TaqMan-based real-time PCR [5] . High-speed RT-qPCR amplification using GeneSoC ® was also performed using SpeedSTAR HS DNA Polymerase (Takara Bio, Inc., Shiga, Japan) with the same primers and probe used for the conventional RT-qPCR [7] . Amplification of SARS-CoV-2 RNA with RT-LAMP was performed with a Loopamp ®︎ 2019-SARS-CoV-2 Detection Reagent Kit (Eiken Chemical, Tokyo, Japan) at 62.5°C for 35 min according to the manufacturer's instructions [8] . For direct RT-LAMP without RNA extraction, the specimen was pretreated with a Viral RNA Extraction Kit (Eiken Chemical). The LUMIPULSE ®︎ SASR-CoV-2 Ag test was performed on a LUMIPULSE ®︎ G1200 (Fujirebio) according to the manufacturer's instructions, and the amount of SARS-CoV-2 antigen was obtained based on the quantitative intensity of the reaction signal. Briefly, each saliva sample was mixed 1:1 with 1× PBS and centrifuged at 20,000 × g for 10 min. The supernatant was used for subsequent analysis on the LUMIPULSE ® G1200 automated system. A total of 85 saliva specimens were collected from 35 hospitalized COVID-19 patients. Table 1) . Samples derived from patients of the early and late phases of COVID-19 tested positive by conventional RT-qPCR at 59.3% and 48.4%, respectively, but there was no difference in the detection rates of viral RNA at both phases (p < 0.371). Samples from the early and late phases tested positive by high-speed RT-qPCR, RT-LAMP, direct RT-LAMP, and LUMIPULSE at rates of 41.9%-63.0%, 45.2%-72.0%, 35.5%-50.0%, and 25.8%-46.3%, respectively. There was no difference in the detection rate of viral RNA in saliva from each phase with any of the detection methods ( Table 1 ). The results of the comparative evaluation of RT-qPCR and other standard diagnostic methods using saliva specimens are summarized in Table 2 . In this study, the κ coefficient value showed diagnostic agreement between RT-qPCR and all tests performed using saliva. The detection rate with all nucleic acid amplification tests and fully-automated antigen testing using saliva specimens evaluated in this study was significantly lower than those in previous reports, demonstrating positive rates of 90% or higher [9] . Above all, the oral cavity is kept clean and wet by salivary flow, and normal physiological activity is maintained by a saliva washout mechanism [10] . Our study suggested that a decrease in saliva production and changes in the oral environment that depended on the patient's conditions, including their age, symptoms such as fever, and disease severity, could affect the detection rate of viral RNA and antigens. The procedure for sampling saliva is advantageous compared with the use of NP swabs: it can be performed easily, does not require specialized personnel, and is comfortable compared with NP swab sampling. However, in a pandemic situation where there is a need to accommodate a large number of patients, it is difficult to standardize the conditions for saliva collection. Further validation is still needed to conclude if saliva-based screening tests for COVID-19 should always be recommended. Saliva is a reliable tool to detect SARS-CoV-2 Saliva as a non-invasive specimen for detection of SARS-CoV-2 Saliva is less sensitive than nasopharyngeal swabs for COVID-19 detection in the community setting Mass screening of asymptomatic persons for SARS-CoV-2 using saliva Comparison of automated SARS-CoV-2 antigen test for COVID-19 infection with quantitative RT-PCR using 313 nasopharyngeal swabs, including from seven serially followed patients Evaluation of a high-speed but low-throughput RT-qPCR system for detection of SARS-CoV-2 Evaluation of rapid diagnosis of novel coronavirus disease (COVID-19) using loop-mediated isothermal amplification Consistent detection of 2019 novel coronavirus in saliva Role of Salivary Biomarkers in Oral Cancer Detection This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.